Close Menu

NEW YORK (GenomeWeb) – DermTech announced today that its licensee, DermTech Canada, has received approval to market the company's pigmented lesions assay (PLA) and noninvasive biopsy kit for melanoma detection in Canada.

As part of the approval, DermTech will market and sell the PLA in Canada, while it will process samples at the company's central laboratory in La Jolla, California. The San Diego-based company said that coverage approvals are in process in Canada with an initial focus on British Columbia and Ontario.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.